| Identification | Back Directory | [Name]
Acetamide, N-[4-[[[3-(1-naphthalenylamino)-2-quinoxalinyl]amino]sulfonyl]phenyl]- | [CAS]
301357-87-9 | [Synonyms]
BMD4503-2
Acetamide, N-[4-[[[3-(1-naphthalenylamino)-2-quinoxalinyl]amino]sulfonyl]phenyl]- | [Molecular Formula]
C26H21N5O3S | [MOL File]
301357-87-9.mol | [Molecular Weight]
483.54 |
| Hazard Information | Back Directory | [Uses]
BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis[1]. | [References]
[1] Choi J, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2018, 28(6): 1116-1121. DOI:10.1016/j.bmcl.2018.01.050 |
|
|